3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
21
Lymphoma, Mantle-Cell
12
Lymphoma, Non-Hodgkin
10
Lymphoma, B-Cell
10
Recurrence
8
Lymphoma
8
Neoplasms
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoblastic Lymphadenopathy
1
Cytokine Release Syndrome
1
Ann Arbor Stage II Mantle Cell Lymphoma
1
Aggression
1
Interventions
midostaurin
2
selinexor
1
pegfilgrastim
1
glofitamab
1
Topotecan
1
Rituximab
1
Prednisone
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Methylprednisolone
1
Immunologic Techniques
1
Ifosfamide
1
Flow Cytometry
1
Etoposide
1
Dexamethasone
1
Clofarabine
1
Carboplatin
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Aggression
×
glofitamab
×
Lymphoid
×
Clear all
NCT06534437
2025-09-29
JASPIS-01
Ryvu Therapeutics SA
Phase 2
Recruiting
178 enrolled